Prognostic factors and outcome of HER2+ breast cancer with CNS metastases
Giovanna Masci(Humanitas University), Armando Santoro(IRCCS Humanitas Research Hospital), Monica Zuradelli(Humanitas University), Giulia Bottai(Humanitas University), Rita De Sanctis(Humanitas University), Elisa Agostinetto(Université Libre de Bruxelles), Laura Giordano(Istituti di Ricovero e Cura a Carattere Scientifico), Agnese Losurdo(Humanitas University), Lorenzo Bello(Institute of Neurological Sciences), Marta Scorsetti(Humanitas University), Rosalba Torrisi(IRCCS Humanitas Research Hospital), Piera Navarria(Fondazione Humanitas per la Ricerca), Fiorenza De Rose
Cited by 12
Related Papers
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
|Radiotherapy and Oncology|2020|646